Agilent Acquires Biocare Medical for $950 Million in Strategic Expansion

Agilent Technologies Inc. has agreed to acquire privately held Biocare Medical in an all-cash transaction valued at $950 million. Biocare, based in the San Francisco Bay Area, specializes in instruments and materials used in cancer research and diagnostics. The deal marks one of Agilent’s largest acquisitions in recent years.

The acquisition will bring Biocare under Agilent’s Life Sciences and Diagnostics Markets Group. Agilent CEO Padraig McDonnell stated the move will 'accelerate innovation and support long-term value creation for our shareholders'. The deal is projected to be accretive to earnings per share within 12 months of closing.

Biocare reported revenue exceeding $90 million in 2025 and offers more than 300 specialized antibodies and reagents. Its portfolio complements Agilent’s existing analytical and clinical technologies. Biocare CEO Luis de Luzuriaga said the acquisition will enhance operational scale and service quality.

Why Did This Happen?

Agilent’s acquisition aligns with its broader strategy to expand capabilities in cancer diagnostics and research. The company has previously made large acquisitions, including BioTek Instruments for $1.17 billion in 2019 and Biovectra for $925 million in 2024. Biocare’s antibody and instrument portfolio will allow Agilent to serve a wider range of labs and research facilities.

The deal also reflects Agilent’s focus on innovation and operational scale in the diagnostics market. Agilent’s stock has declined 15% this year, reaching a market valuation of $32.5 billion. The acquisition is expected to offset some of this pressure by adding high-growth capabilities.

Who Was Involved in the Transaction?

Biocare is being sold by an investor group led by Excellere Partners and GHO Capital Partners. Excellere is a Denver-based private equity firm with $2.3 billion in committed capital. GHO is a London-based healthcare investment adviser.

Financial advisors for the transaction included Jefferies Financial Group Inc., which served as the exclusive financial adviser for Excellere, GHO, and Biocare. Agilent was advised by Barclays Plc. Legal counsel was provided by Ropes & Gray LLP for the seller group and Sullivan & Cromwell LLP for Agilent.

What Is the Timeline for Completion?

The transaction is expected to close by the end of Agilent’s fiscal fourth quarter, which ends on October 31. Agilent will integrate Biocare into its operations over the following months.

Agilent has experienced strong revenue growth in recent years, including a 7% increase in 2025 and an EPS of $4.58. The company also has a robust free cash flow of $830 million, supporting continued investments and acquisitions.

Biocare’s integration is expected to accelerate Agilent’s innovation pipeline and strengthen its position in the life sciences and diagnostics market. The move aligns with broader industry trends in cancer research and diagnostics.

What Are Analysts Watching Next?

Analysts have varied views on Agilent’s future performance. The stock has an average price target of $162.83, representing a 34.15% potential upside. Baird recently cut its price target to $155 from $165, while maintaining an Outperform rating.

Investors are watching Agilent’s ability to integrate Biocare effectively and achieve the expected EPS benefits. The company’s forward P/E ratio stands at 18.48, reflecting investor confidence in future earnings growth.

Agilent’s recent performance includes a revenue guidance raise to $7.30 billion to $7.50 billion for fiscal 2026. The company has also returned capital to shareholders through share repurchases and dividends.

The Biocare acquisition is Agilent’s largest since 2019 and represents a major step in its expansion strategy. The deal adds specialized capabilities in cancer research and strengthens Agilent’s position in the diagnostics market.